120 related articles for article (PubMed ID: 15799868)
21. A novel series of highly selective inhibitors of MMP-3.
Whitlock GA; Dack KN; Dickinson RP; Lewis ML
Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
[TBL] [Abstract][Full Text] [Related]
22. Galloyl cyclic-imide derivative CH1104I inhibits tumor invasion through suppressing matrix metalloproteinase activity.
Chen MH; Cui SX; Cheng YN; Sun LR; Li QB; Xu WF; Ward SG; Tang W; Qu XJ
Anticancer Drugs; 2008 Nov; 19(10):957-65. PubMed ID: 18827560
[TBL] [Abstract][Full Text] [Related]
23. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
24. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
26. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.
Hugenberg V; Riemann B; Hermann S; Schober O; Schäfers M; Szardenings K; Lebedev A; Gangadharmath U; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
J Med Chem; 2013 Sep; 56(17):6858-70. PubMed ID: 23899323
[TBL] [Abstract][Full Text] [Related]
27. Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging.
Breyholz HJ; Wagner S; Faust A; Riemann B; Höltke C; Hermann S; Schober O; Schäfers M; Kopka K
ChemMedChem; 2010 May; 5(5):777-89. PubMed ID: 20373323
[TBL] [Abstract][Full Text] [Related]
28. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo.
Breyholz HJ; Wagner S; Levkau B; Schober O; Schäfers M; Kopka K
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):24-32. PubMed ID: 17372570
[TBL] [Abstract][Full Text] [Related]
29. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
[TBL] [Abstract][Full Text] [Related]
30. Novel matrix metalloproteinase inhibitors derived from quinoxalinone scaffold (Part I).
Li Y; Zhang J; Xu W; Zhu H; Li X
Bioorg Med Chem; 2010 Feb; 18(4):1516-25. PubMed ID: 20097082
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process.
Amano S; Ogura Y; Akutsu N; Matsunaga Y; Kadoya K; Adachi E; Nishiyama T
Br J Dermatol; 2005 Dec; 153 Suppl 2():37-46. PubMed ID: 16280020
[TBL] [Abstract][Full Text] [Related]
32. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.
Hugenberg V; Breyholz HJ; Riemann B; Hermann S; Schober O; Schäfers M; Gangadharmath U; Mocharla V; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
J Med Chem; 2012 May; 55(10):4714-27. PubMed ID: 22540974
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.
Santos MA; Enyedy EA; Nuti E; Rossello A; Krupenko NI; Krupenko SA
Bioorg Med Chem; 2007 Feb; 15(3):1266-74. PubMed ID: 17127067
[TBL] [Abstract][Full Text] [Related]
34. Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.
Le Diguarher T; Chollet AM; Bertrand M; Hennig P; Raimbaud E; Sabatini M; Guilbaud N; Pierré A; Tucker GC; Casara P
J Med Chem; 2003 Aug; 46(18):3840-52. PubMed ID: 12930146
[TBL] [Abstract][Full Text] [Related]
35. The effect of a hydroxamic acid-containing polymer on active matrix metalloproteinases.
Skarja GA; Brown AL; Ho RK; May MH; Sefton MV
Biomaterials; 2009 Apr; 30(10):1890-7. PubMed ID: 19147221
[TBL] [Abstract][Full Text] [Related]
36. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
37. A new role for old ligands: discerning chelators for zinc metalloproteinases.
Jacobsen FE; Lewis JA; Cohen SM
J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
[TBL] [Abstract][Full Text] [Related]
38. Rapid assembly of matrix metalloprotease inhibitors using click chemistry.
Wang J; Uttamchandani M; Li J; Hu M; Yao SQ
Org Lett; 2006 Aug; 8(17):3821-4. PubMed ID: 16898826
[TBL] [Abstract][Full Text] [Related]
39. Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.
Becker DP; Barta TE; Bedell LJ; Boehm TL; Bond BR; Carroll J; Carron CP; Decrescenzo GA; Easton AM; Freskos JN; Funckes-Shippy CL; Heron M; Hockerman S; Howard CP; Kiefer JR; Li MH; Mathis KJ; McDonald JJ; Mehta PP; Munie GE; Sunyer T; Swearingen CA; Villamil CI; Welsch D; Williams JM; Yu Y; Yao J
J Med Chem; 2010 Sep; 53(18):6653-80. PubMed ID: 20726512
[TBL] [Abstract][Full Text] [Related]
40. The synthesis and preliminary activity assay in vitro of peptide-like derivatives as APN inhibitors.
Li SH; Li G; Huang HM; Xiong F; Liu CM; Tu GG
Arch Pharm Res; 2008 Oct; 31(10):1231-9. PubMed ID: 18958412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
